Purpose. The effects of altering the dynamics of phase inversion of a polyl
actic glycolic acid (PLGA) solution depot on the sustained-release delivery
profile of human growth hormone (hGH) were evaluated. The impact of adjust
ing the protein particle composition was also studied in a slow phase-inver
ting formulation.
Methods. Protein release profiles of depots prepared from four model solven
ts were generated by injecting formulations into the subcutaneous space of
normal rots and monitoring hGH serum levels over the course of 1 month. Sca
nning electron microscopy, Coulometric Karl Fischer titration, size-exclusi
on liquid chromatography, and reversed-phase liquid chromatography were use
d to observe depot morphologies, bulk water absorption, PLGA degradation, a
nd protein particle dissolution rates, respectively.
Results. An extended-release profile and significantly reduced burst effect
resulted when the aqueous affinity of the depot solvent was reduced. As se
en earlier in in vitro experiments, lowering the solvent's aqueous affinity
slows the phase inversion rate, which in turn produces depot morphologies
favorable to prolonged release. Protein burst on injection was entirely eli
minated in a slow phase-inverting formulation by densifying the lyophilized
protein particles. Unlike the use of metal cations to prolong release of s
ome proteins in PLGA microsphere depots, this technique is more universal,
and thus is potentially usable with any protein or highly soluble drug agen
t. The onset of biodegradation was observed to occur at 14 days for all dep
ot formulations, however the bulk biodegradation rate slowed as the aqueous
affinity of the depot solvent decreased. This result supports the hypothes
is that, in a slow phase-inverting system, drug release over the first few
weeks is governed by the diffusion rate of drug through the polymer solutio
n.
Conclusions. By taking advantage of the effects of low aqueous affinity and
protein particle densification, a PLGA solution depot was produced with th
e capability of sustaining hGH levels in normal rats at a serum level of ID
to 200 ng/ml for 28 days.